Fiscal Period | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|
Period End Date | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
Cash | 31.82 | 55.76 | 22.05 | 0.11 |
Cash Equivalents | 269.60 | 228.06 | 490.11 | 115.49 |
Cashand Short Term Investments | 301.41 | 283.82 | 512.16 | 115.60 |
Accounts Receivable- Trade Net | 765.43 | 806.77 | 673.49 | 619.50 |
Total Receivables Net | 931.95 | 918.31 | 715.21 | 726.84 |
Total Inventory | 681.13 | 621.86 | 516.24 | 513.42 |
Prepaid Expenses | 0.81 | 0.14 | 0.16 | 0.94 |
Other Current Assets Total | 0.70 | 26.22 | 20.81 | 42.24 |
Total Current Assets | 1,916.00 | 1,850.34 | 1,764.58 | 1,399.04 |
Property/ Plant/ Equipment Total- Gross | 1,095.56 | 975.87 | 789.32 | 656.26 |
Accumulated Depreciation Total | -199.36 | -151.62 | -112.99 | -77.28 |
Property/ Plant/ Equipment Total- Net | 896.20 | 824.24 | 676.34 | 578.99 |
Intangibles Net | 14.85 | 18.00 | 10.38 | 7.91 |
Long Term Investments | 0.08 | 0.08 | 5.64 | 8.62 |
Note Receivable- Long Term | 12.26 | 1.27 | 0.00 | 1.15 |
Other Long Term Assets Total | 11.03 | 8.21 | 14.07 | 1.36 |
Total Assets | 2,850.41 | 2,702.15 | 2,471.01 | 1,997.08 |
Accounts Payable | 368.66 | 427.23 | 307.72 | 221.31 |
Accrued Expenses | 28.43 | 8.38 | 42.06 | 20.43 |
Notes Payable/ Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
Current Portof LT Debt/ Capital Leases | 2.39 | 2.26 | 1.68 | - |
Other Currentliabilities Total | 39.30 | 58.68 | 32.54 | 979.70 |
Total Current Liabilities | 438.77 | 496.54 | 384.00 | 1,221.44 |
Capital Lease Obligations | 14.76 | 17.09 | 1.20 | - |
Total Long Term Debt | 14.76 | 17.09 | 1.20 | 0.00 |
Total Debt | 17.15 | 19.36 | 2.88 | 0.00 |
Deferred Income Tax | 48.79 | 42.43 | 31.49 | 22.89 |
Other Liabilities Total | 15.77 | 7.87 | - | - |
Total Liabilities | 518.09 | 563.94 | 416.70 | 1,244.33 |
Common Stock Total | 24.51 | 24.51 | 24.51 | 1.96 |
Additional Paid- In Capital | 1,004.96 | 1,004.96 | 1,004.96 | - |
Retained Earnings( Accumulated Deficit) | 1,302.86 | 1,108.75 | 1,024.85 | 750.79 |
Total Equity | 2,332.32 | 2,138.21 | 2,054.31 | 752.75 |
Total Liabilities Shareholders' Equity | 2,850.41 | 2,702.15 | 2,471.01 | 1,997.08 |
Total Common Shares Outstanding | 12.25 | 12.25 | 12.25 | 12.25 |
Tangible Book Valueper Share Common Eq | 189.14 | 173.04 | 166.81 | 60.79 |
period Length | 0.00 | 0.00 | 0.00 | 0.00 |
Alivus Life Sciences Dividend Alivus Life Sciences Bonus Alivus Life Sciences News Alivus Life Sciences AGM Alivus Life Sciences Rights Alivus Life Sciences Splits Alivus Life Sciences Board Meetings Alivus Life Sciences Key Metrics Alivus Life Sciences Shareholdings Alivus Life Sciences Profit Loss Alivus Life Sciences Cashflow Alivus Life Sciences Q1 Results Alivus Life Sciences Q2 Results Alivus Life Sciences Q3 Results Alivus Life Sciences Q4 Results
Top GainersTop LosersIndian IndicesBSE Active StocksNSE Active Stocks